Quantcast

Latest Panitumumab Stories

2010-08-19 08:36:00

ROME, August 19, 2010 /PRNewswire/ -- Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) and published in the British Journal of...

2010-08-11 08:20:00

THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix® (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer.

2010-06-29 08:10:00

QUEBEC CITY, June 29 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.

2010-06-29 08:00:00

NEW YORK, June 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs.

2010-05-20 17:08:00

THOUSAND OAKS, Calif., May 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company's oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4( )- 8, 2010 in Chicago. "Cancer is a complex disease that requires a comprehensive approach.

2010-04-12 08:29:00

THOUSAND OAKS, Calif., April 12 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents and a comprehensive biomarker analysis will be presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

2010-04-08 07:35:00

Phase 3 X-PECT Trial (Xeloda(R)) + Perifosine Evaluation in Colorectal Cancer Treatment) being conducted by partner Keryx Biopharmaceuticals pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, April 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.

2010-04-05 07:40:00

QUEBEC CITY, April 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.


Word of the Day
ultimo
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
The word 'ultimo' comes from the Latin phrase 'ultimo mense', 'in the last month'.
Related